Tumor regression was also observed in metastatic melanoma lesions with CP870, 893 where CD40 is less likely to be expressed, altogether suggesting that agonism contributes to efficacy.(78) Transient peripheral blood B-cell depletion and upregulation of CD86 on residual B cells were observed in some participants, alongside elevation of inflammatory cytokines. The gene discussed is CD40; the disease is neoplasm.